MEDICATION ADHERENCE AND ITS IMPACT ON RELAPSE PREVENTION IN PATIENTS WITH SCHIZOPHRENIA: A TERTIARY CARE HOSPITAL-BASED STUDY FROM NORTH INDIA
Main Article Content
Keywords
Schizophrenia; medication adherence; relapse prevention; antipsychotics; psychiatric disorders; North India
Abstract
Background: Schizophrenia is a chronic psychiatric disorder characterized by recurrent relapses, often driven by poor medication adherence. Non-adherence remains a major challenge, particularly in low-resource settings, leading to increased morbidity and hospitalization.
Objectives: To assess medication adherence among patients with schizophrenia and evaluate its association with relapse prevention in a tertiary care hospital in North India.
Methods: This hospital-based prospective observational study was conducted from March 2021 to October 2021 among 40 patients diagnosed with schizophrenia. Sociodemographic and clinical data were collected using a structured proforma. Medication adherence was assessed using a standardized adherence scale along with caregiver reports. Relapse was defined as worsening of symptoms requiring treatment modification or hospitalization. Statistical analysis was performed using SPSS version 25, and associations were tested using Chi-square test with significance set at p < 0.05.
Results: Among 40 patients, 35% showed high adherence, 40% moderate adherence, and 25% low adherence. Low adherence was associated with the highest relapse rate (80%), while high adherence showed significantly fewer relapses (14%). Poor insight, inadequate family support, and medication side effects were significantly associated with non-adherence.
Conclusion: Medication adherence is a key determinant of relapse prevention in schizophrenia. Strengthening adherence through psychoeducation, caregiver involvement, and regular follow-up can significantly improve clinical outcomes.
References
2. Kane JM. Treatment adherence and long-term outcomes. CNS spectrums. 2007 Jan;12(S17):21-6.
3. Chaudri NA. Adherence to long-term therapies evidence for action.
4. Patel V, Flisher AJ, Hetrick S, McGorry P. Mental health of young people: a global public-health challenge. The lancet. 2007 Apr 14;369(9569):1302-13.
5. American Psychiatric Association. The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. American Psychiatric Association; 2016 May 3.
6. Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, Davis JM. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. The Lancet. 2012 Jun 2;379(9831):2063-71.
7. Thara R, Padmavati R, Srinivasan TN. Focus on psychiatry in India. The British Journal of Psychiatry. 2004 Apr;184(4):366-73.
8. National Collaborating Centre for Mental Health (UK. Psychosis and schizophrenia in adults: treatment and management.
9. Higashi K, Medic G, Littlewood KJ, Diez T, Granström O, De Hert M. Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review. Therapeutic advances in psychopharmacology. 2013 Aug;3(4):200-18.
10. Ascher-Svanum H, Zhu B, Faries DE, Salkever D, Slade EP, Peng X, Conley RR. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC psychiatry. 2010 Jan 7;10(1):2.
11. Ascher-Svanum H, Zhu B, Faries DE, Salkever D, Slade EP, Peng X, Conley RR. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC psychiatry. 2010 Jan 7;10(1):2.
12. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England journal of medicine. 2005 Sep 22;353(12):1209-23.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Dr Madhawendra Sinha
Associate Professor, Department of Psychiatry, M G M Medical College, Kishanganj, Bihar, India.
Dr Mayank Rai
Assistant Professor, Department of Psychiatry, I. Q. City Medical College, Durgapur, West Bengal, India.
Dr Abhishek
Assistant Professor, Department of Psychiatry, Varun Arjun Medical College, Sahjahanpur, Uttar Pradesh, India.
